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Human leukocyte antigen (HLA)-G molecule, a non-classical HLA-Ib molecule, is less poly-
morphic when compared to classical HLA class I molecules. Human leukocyte antigen-G
(HLA-G) was first detected on cytotrophoblast cells at the feto-maternal interface but its
expression is prevalent during viral infections and several autoimmune diseases. HLA-G
gene is characterized by polymorphisms at the 3′ un-translated region and 5′ upstream
regulatory region that regulate its expression and are associated with autoimmune dis-
eases and viral infection susceptibility, creating an unbalanced and pathologic environment.
This review focuses on the role of HLA-G genetic polymorphisms, mRNA, and protein
expression in autoimmune conditions and viral infections.
Keywords: HLA-G, inflammation, autoimmunity, infection, regulation
INTRODUCTION
Human Leukocyte Antigen-G (HLA-G) is a functional molecule
belonging to class Ib human leukocyte antigens (HLA) charac-
terized by a non-covalent link between β2-microglobulin (β2m)
and glycoprotein heavy chain. The gene is located within Major
Histocompatibility Complex (MHC) locus on chromosome 6 (1,
2). HLA-G products show some peculiar features for which they
are considered as non-classical HLA-I antigens: (1) the limitation
of their allelic polymorphism (3); (2) the expression of seven iso-
forms represented by four membrane-bound (G1, G2, G3, and
G4) and three soluble (G5, G6, and G7) proteins (4); and (3)
the restriction of their tissue distribution (5). Polymorphisms
at the 5′ upstream regulatory region and at the 3′ UTR of the
HLA-G gene play an important role in the regulation of HLA-
G production (6). Mainly, two polymorphisms at the 3′ UTR: a
deletion/insertion (DEL/INS) of 14 base pairs (14bp) polymor-
phism (rs371194629) and a C >G single-nucleotide polymor-
phism (SNP) at the +3142bp position (rs1063320) (7) (Figure 1)
are able to affect mRNA stability in vivo and protein production
and implicated in pathological conditions: 14bpINS allele is associ-
ated with mRNA instability (8, 9);+3142G allele creates a binding
site for three microRNAs (miRNAs) (miR-148a, miR-148b, and
miR-152) reducing soluble protein production (10). These obser-
vations suggest that 14bpINS/INS and +3142G/G genotypes are
associated with a lower HLA-G production than 14bpDEL/INS
and DEL/DEL,+3142C/G, and C/C genotypes (8, 10).
Membrane-bound HLA-G1 and soluble HLA-G5 (HLA-G5)
represent the mainly expressed and investigated HLA-G isoforms
(1) and are currently supposed to be the most important and
functional isoforms (11). However, while HLA-G5 molecules are
actively secreted as soluble isoforms, HLA-G1 proteins could
be released by proteolytic shedding from cell surface (sHLA-
G1) via matrix metalloproteinase-2 (MMP-2) (12–16). HLA-G
can exist as β2m-associated and -free monomers (17, 18) and
as disulfide-linked dimers or multimers (17, 19, 20). HLA-G
disulfide-linked dimers are linked by disulfide bonds between two
cysteine residues at position 42 of the HLA-G alpha-1 domain
(19–21) and present higher affinity for ILT-2 and ILT-4 recep-
tors compared to monomers (22, 23). Placental trophoblast cells
(24), thymus (25), cornea (26), nail matrix (27), pancreas (28),
erythroid, and endothelial precursors (29) present a physiological
expression of HLA-G molecules. However, HLA-G can be ectopi-
cally expressed also on monocytes (30), in transplantation, tumors,
viral infections, and autoimmune diseases (1, 2). HLA-G antigens
are currently considered as immune-modulatory molecules due
to their role in preserving immune tolerance at the feto-maternal
interface (31), promoting graft tolerance (32), reducing inflamma-
tory and immune responses (33), favoring tumors (34), and virus
infection via immune escape (35). Both membrane-bound and
soluble HLA-G antigens exert their immune-suppressive proper-
ties: (a) inhibiting the activity and inducing apoptosis of cytotoxic
CD8+ T cells and NK cells (36–38); (b) inhibiting the prolifera-
tion of CD4+ T cells that are shifted to an immune-suppressive
profile (39, 40); (c) inhibiting antigen-presenting cells and B cell
differentiation (41, 42); (d) inducing a Th2 polarization (43);
and (e) inducing regulatory T cells (44) and Interleukin (IL)-10
secreting dendritic cells (DC10) (45) (Figure 2). The interactions
between HLA-G proteins and their specific inhibitory receptors
ILT-2 (LILRB1/CD85j), ILT-4 (LILRB2/CD85d), and KIR2DL4
(CD158d) expressed by immune cells (46) account for the effects
of these molecules on immune cells.
Moreover, HLA-G expression is up-regulated by the secretion
of anti-inflammatory cytokines such as IL-10 which, in its turn,
is enhanced by HLA-G (30). For these reasons, the implication of
HLA-G molecules in inflammatory, immune-mediated, and infec-
tive conditions has been investigated (47, 48). The knowledge of
www.frontiersin.org November 2014 | Volume 5 | Article 592 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rizzo et al. HLA-G in autoimmunity and infection
FIGURE 1 | Human leukocyte antigen-G gene. UTR, un-translated region.
FIGURE 2 | Human leukocyte antigen-G is an anti-inflammatory molecule inhibiting and controlling immune cell activation. NK, natural killer cells; Tr1,
type 1 regulatory T cells; DC, dendritic cell; Treg, regulatory T cell; FasR, Fas receptor; DC10, IL-10-differentiated dendritic cells.
the interactions between HLA-G molecules and immune mecha-
nisms and their implication in pathological conditions may assist
in improving our knowledge on the mechanisms at the basis of
several autoimmune diseases and viral infections.
HLA-G AND GASTROINTESTINAL DISEASES
Celiac disease is a gluten sensitivity, which induces an inflam-
mation that damages the villi in the small intestine of genetically
predisposed subjects. Both genetic and environmental factors con-
tribute to the development of celiac disease (CD). Torres and
coauthors (49) have shown the presence of HLA-G in biopsies
from celiac patients and have observed higher sHLA-G amounts
in comparison with control subjects. The evaluation of the 14bp
INS/DEL polymorphism in a group of 522 celiac patients (50),
subdivided accordingly with the presence of HLA-DQ2 mole-
cule, encoded by DQA1*05/DQB1*02 genes, has demonstrated
an increased frequency of the 14bp INS/INS genotype in com-
parison with controls. These data suggest that the 14bp INS allele
may increase the risk of gut inflammation, most likely leading to
chronicity. Ulcerative colitis (UC) and Crohn’s disease are charac-
terized by a different sHLA-G expression pattern (51) by periph-
eral blood mononuclear cells. Non-activated peripheral blood
mononuclear cells from Crohn’s disease patients secrete sponta-
neously sHLA-G while those from UC patients and healthy donors
do not. Furthermore, after stimulation with LPS, both cells from
Crohn’s disease and healthy subjects show sHLA-G production,
while this does not happen in UC patients. The different HLA-G
expression profiles in UC and Crohn’s disease patients sustain the
different aethiopathogenesis at the origin of these two diseases.
In particular, the responses to therapies in UC and Crohn’s dis-
ease correspond to different sHLA-G secretion levels (52). The
immunosuppressant therapy normalizes the production of HLA-
G molecules in Crohn’s disease while it starts the release of HLA-G
in UC patients. These data confirm the diversity in the behavior
of these two pathologies and propose the analysis of sHLA-G lev-
els with the final goal of distinguishing between UC and Crohn’s
disease patients and to monitor therapy.
HLA-G AND RHEUMATOLOGIC DISEASES
Rheumatic diseases are inflammatory and autoimmune diseases,
which are the second most common cause of disability after
musculoskeletal injuries. Rheumatoid arthritis (RA) is an autoim-
mune disease caused by the immune system attacking synovial
cells. A combination of genetic and environmental factors may
increase the risk of RA. Gene expression profiles (GEPs) in bone
marrow-derived RA mononuclear cells (53) have shown 1,910
down-regulated and 764 up-regulated gene, which include the
HLA-G gene. Several studies have evaluated the role of HLA-
G polymorphisms in RA susceptibility without reaching a final
common result. The evaluation on 256 RA patients and 356
healthy controls genotyped for the HLA-G 14bp INS/DEL poly-
morphism has reported no differences in allelic and genotypic
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frequencies and no correlation with disease characteristics (54).
The analysis of two SNPs (rs1736936, −1305G/A and rs2735022,
−689A/G) in HLA-G promoter in the Korean population has
not presented any connection to the development of RA (55).
The evaluation in a Brazilian cohort documented the impli-
cation of 3′ UTR polymorphisms in RA follow-up (56). The
authors have observed a significant association of the−762C >T,
−716T >G, −689A>G, −666G>T, −633G>A, −486A>C,
and −201G>A (rs1632946 ; rs2249863; rs2735022; rs35674592;
rs1632944; rs1736933; and rs1233333) SNPs with the disease. The
analysis of 106 patients with juvenile idiopathic arthritis (JIA) has
shown an association between JIA female susceptibility and the
14 bp DEL allele. These different associations support the pres-
ence of different pathogenic elements between RA and JIA (54).
RA (57) and JIA patients present lower serum sHLA-G concen-
tration than in controls (58), with a possible contribution to the
chronicity of the inflammation. On the contrary, JIA synovial flu-
ids showed higher sHLA-G levels than controls (SF) (56). Since
we have observed that HLA-G molecules are enhanced in synovial
fibroblasts from inflamed joints (59) and that high sHLA-G levels
correlate with disease activity (57), we may suggest an impaired
control of immune reaction at joint, which characterizes JIA dis-
ease. The HLA-G 14bp INS/DEL polymorphism has also been
evaluated as a marker for RA therapy. Methotrexate (MTX), a
disease-modifying anti-rheumatic drug (DMARD), induces an
increased production of IL-10 in RA patients with a better ther-
apeutic response (60) and is able to enhance HLA-G secretion
by peripheral blood mononuclear cells (61). Interestingly, the
14bp DEL/DEL genotype is increased in RA patients with a good
response to MTX therapy (62), with a possible implication in the
control of immune activation. It must be underlined, however,
that contrasting results have been obtained (63, 64), possibly due
to a different dosage of MTX, a different cut-off value for RA ther-
apy response assessment. Scleroderma (SSc) is an autoimmune
rheumatic disease of the connective tissue (65). Only SSc patients
with a longer survival, lower frequency of vascular cutaneous
ulcers, telangiectasias, and inflammatory polyarthralgia present
HLA-G molecule expression in skin biopsies (66) suggesting an
implication of this molecule on the control of immune response
at the skin level.
Systemic lupus erythematosus is a systemic autoimmune dis-
ease of the connective tissue that can affect any part of the body.
The immune response is mainly characterized by Th2-cell pre-
dominance. Rosado and coauthors (67) and Chen and coauthors
(68) have shown higher sHLA-G and IL-10 levels in systemic lupus
erythematosus (SLE) patients in comparison with healthy con-
trols, while Rizzo and coauthors (69) have observed lower sHLA-G
concentrations in SLE patients (70). Interesting, the analysis of
monocytes and mature CD83 positive dendritic cells from SLE
patients has evidenced a diminished expression of HLA-G in com-
parison with healthy controls (71), a lower HLA-G expression in
response to IL-10 and a lower HLA-G trogocytosis from autolo-
gous monocytes compared with controls. Using the SNPs mapping
approach, HLA-G gene is recognized as a novel independent locus
for SLE (72). In particular, HLA-G 14bp INS/DEL polymorphism
and HLA-G +3142C >G SNP have been analyzed in a SLE pop-
ulation. SLE patients showed a higher frequency of 14bp INS
allele and 14bp INS/INS genotype (69) and the heterozygote group
showed lower systemic lupus erythematosus disease activity index
(SLEDAI) indexes than homozygous groups (73). On the con-
trary, the evaluation of HLA-G 14bp INS/DEL polymorphism in
a SLE Brazilian population did not present an association (74),
while the +3142G allele and the +3142 GG genotype frequencies
were increased among SLE patients as compared with controls
(75, 76). These data sustain a possible role of HLA-G expression in
modifying SLE condition. Behçet (BD) and Kawasaki diseases are
autoimmune vasculitis. The HLA-G*01:01:01 allele is associated
with a reduced risk of BD while HLA-G*01:01:02 and G*01:05N
alleles are associated with an increased risk of BD (77, 78). Non-
synonymous SNP (+755A/C) of the HLA-G gene (rs12722477,
G*01:04) is significantly associated with Kawasaki disease (79).
These data suggest an influence of HLA-G polymorphisms in
determining disease risk, possibly affecting HLA-G production
and consequently inflammation status.
HLA-G AND CUTANEOUS DISEASES
The skin is characterized by a “skin immune system (SIS),”
where immune cells and humoral components support cutaneous
inflammation. The deregulation of skin defense mechanisms is
evident in a large variety of inflammatory disorders of the skin,
such as psoriasis, atopic dermatitis, pemfigo, vitiligo, and systemic
sclerosis (80). HLA-G protein is not expressed in the skin from
healthy controls (81, 82). Ectopic HLA-G expression has been
described in skin pathologies (83–86).
Psoriasis is a chronic inflammatory skin disease with an autoim-
mune component. Both membrane-bound and soluble HLA-G
proteins have been detected in psoriatic skin lesions with the main
compound characterized by macrophage lining at the dermo-
epidermal junctions (82). The up-regulation of HLA-G mol-
ecules by macrophages could represent an attempt to control
auto-reactive T cells, induced by activated keratinocytes-derived
cytokines/chemokines. HLA-G may prevent keratinocyte destruc-
tion by modulating the activity of cytotoxic lymphocytes and
promoting the development of Treg cells (87). Interestingly, signif-
icantly lower plasma sHLA-G levels have been found in psoriatic
patients compared with controls (88), suggesting a difference in
systemic HLA-G expression that could be associated with the IL-
10 deficiency typical of psoriasis. Psoriasis management can be
divided into three main types: topical drugs, light therapy, and
systemic medications. Evaluation of therapeutic effects on sHLA-
G expression has shown an increase in plasmatic levels of systemic
treated patients (efalizumab, cyclosporin A, and acitretin) (88)
and a significant association between HLA-G 14bp DEL allele and
14bp DEL/DEL genotype with acitretin clinical outcome (89). We
can suppose a possible direct effect of HLA-G in antagonizing sys-
temic T helper 1 activation and with a potential role as a marker
of response to acitretin in psoriatic patients.
Pemphigus vulgaris is a blistering disease caused by autoanti-
bodies to desmoglein skin adhesion proteins. Skin tissue sections
from pemphigus vulgaris (PV) patients express detectable HLA-G
molecules at both transcriptional and translational levels, while
control sections present only HLA-G transcription (90). More-
over, the HLA-G 14bp DEL allele has been observed with higher
frequency in PV patients in comparison with controls in a Jewish
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population (91). These data suggest that HLA-G expression could
be a detrimental factor for the development of PV.
HLA-G AND DIABETES
Type 1 and type 2 diabetes present immunologic defects that
enhance insulin resistance as a result of genetics sedentary lifestyle,
obesity, and other conditions, such as chronic inflammation or
infection. It has been shown that higher levels of sHLA-G are fre-
quent in subjects with an impaired glucose metabolism (92). These
data suggest a possible implication of HLA-G antigens in the dia-
betic condition. In fact, SNPs rs4122198, rs2394186, rs1619379, and
rs1611133 near the HLA-G gene have been associated with type 1
diabetes (93); dendritic cells from type 1 diabetic patients produce
lower HLA-G molecules in response to IFN-beta (94) in compari-
son with control subjects and the HLA-G 14bp INS-INS genotype
might contribute to the development of high blood pressure in
type 2 diabetes (95).
Interestingly, HLA-G has been found in some secretory gran-
ules and on the cell surface of primary islet cells induced to secrete
insulin (28). On the basis of these data, it could be hypothe-
sized that an impaired HLA-G expression at pancreatic islets could
sustain T cell activation and onset of diabetes.
HLA-G IN MULTIPLE SCLEROSIS
Multiple sclerosis is the prototypic autoimmune disease of the cen-
tral nervous system (CNS) characterized by chronic inflammatory
demyelination and neurodegeneration of unidentified origin (96).
Multiple sclerosis (MS) typically occurs in young adults and man-
ifests in women twice as frequently as in men with neurological
symptoms and signs, called relapses, which are usually dissem-
inated in space and time (97). About the 80% of MS patients
present a disease onset with a relapsing–remitting (RR) form fol-
lowed by a secondary progressive (SP) course that arises after years,
whereas MS starts with a primary progressive (PP) form in approx-
imately the 20% of subjects (98). However, the recent proposed
criteria (99) suggest that the coexistence of multi-focal lesions in
the periventricular white matter on T2-weighted Magnetic Res-
onance Imaging (MRI) scans with or without Gadolinium (Gd)
enhancement on T1-weighted MRI scans are needed for the diag-
nosis of MS. Based on epidemiological studies, exposure to an
environmental factor, e.g., an infectious agent, in genetically pre-
disposed individuals is currently thought to be crucial for MS
pathogenesis (100) in which the traffic into the CNS of activated
auto-reactive CD4+ T helper 1 (Th1) cells plays a central role
(96, 101, 102). The initiation of brain inflammation is due to the
activation of microglia by infiltrating CD4+ T cells leading to
the generation of Th1-mediated immune responses (IL-12/IFN-γ
and IL-23/IL-17), while the resolution of neuroinflammation is
triggered by astrocytes, which promote anti-inflammatory Th2-
polarized responses (IL-10 and TGF-β) and the elimination of
infiltrating immune cells through Fas/FasL-dependent apoptosis
(96, 101) (Figure 3).
FIGURE 3 | Intrathecal immune milieu in MS. The secretion of HLA-G5
in dimeric form by macrophages and HLA-Gpos Treg infiltrating the central
nervous system (CNS) across the blood–brain barrier (BBB), endothelial
cells, and microglia, sustained by a IL-10 release by astrocytes, may
promote the suppression of CD4+ Th1 cell activity and the apoptotic
removal of CD8+ T cells and NK cells that favor the formation of an
anti-inflammatory intrathecal microenvironment leading to the
termination of MS inflammation.
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A growing body of evidence indicates that sHLA-G antigens
may have a tolerogenic role in MS (102, 103). Cerebrospinal fluid
(CSF) detectable sHLA-G has been detected in RRMS patients with
higher levels in comparison with other inflammatory neurologi-
cal disorders (OIND), non-inflammatory neurological disorders
(NIND), and controls (104). Furthermore, higher CSF sHLA-G
levels have been detected in RRMS without MRI evidence com-
pared to those with MRI active disease. Notably, a positive corre-
lation between CSF concentrations of sHLA-G and IL-10 has been
found in MS patients without MRI evidence of active disease.
Therefore, CSF levels of sHLA-G may act, together with IL-10,
as anti-inflammatory molecules to regulate MS disease activity.
The association between elevated CSF sHLA-G levels and clini-
cal and MRI appearance of MS stable disease is supported by the
intrathecal synthesis of sHLA-G in MS clinically and MRI inac-
tive patients (105). We have found higher CSF levels of HLA-G5
and not of sHLA-G1 isoforms compared with controls and in
presence rather than in absence of MRI Gd enhancing lesions
(106) and an as well as inverse correlation between CSF levels of
sHLA-G and anti-apoptotic sFas molecules in MS patients with-
out MRI disease activity (107). Collectively, these results suggest
a strong correlation between high CSF levels of sHLA-G anti-
gens and the resolution of MS autoimmunity probably related to
the anti-inflammatory properties of these molecules. The impact
of HLA-G in MS pathogenesis was recently confirmed by other
studies, which demonstrated that: (a) Th1 and Th2 cytokine pro-
duction and CD4+ T cell proliferation are suppressed by HLA-G
from MS patient peripheral blood monocytes during the first
month of treatment with IFN-β (108); (b) MS disease activity
during pregnancy may be modulated by tolerogenic properties
of sHLA-G since post-partum serum sHLA-G levels are higher
in MS patients without clinical attacks (109); and (c) microglia,
macrophages, and endothelial cells located within and around
MS lesions present a strong immunohistochemical expression of
HLA-G and its inhibitory receptors (ILT-2 and ILT-4), with an
elevated protein HLA-G expression on cultured human microglial
cells after activation with Th1 pro-inflammatory cytokines (110).
Meanwhile, a novel subpopulation of naturally occurring CD4+
and CD8+ regulatory T cells of thymic origin expressing HLA-
G (HLA-Gpos Treg), has been characterized in MS patients with
a suppressive activity through the secretion of HLA-G5 and
the shedding of sHLA-G1 (111–113). Overall, these data sus-
tain anti-inflammatory properties of sHLA-G molecules, and in
particular HLA-G-5 isoform, which could lead to the remission
of MS autoimmunity. Although it has been demonstrated that
SNP rs4959039, a SNP in the downstream un-translated region
of HLA-G gene is independently associated with MS susceptibility
(114), the possible link between HLA-G genetic polymorphisms
and MS has not been intensively explored (102, 103). Conflict-
ing results have been obtained. Although no association between
HLA-G gene polymorphism and MS or severity of the disease
has been initially found (115), 14bpINS and −725G (rs1233334)
alleles have been shown to be related to MS (116). However,
a recent study, evaluating the influence of 14bpDEL/INS and
+3142C >G HLA-G polymorphisms on CSF and serum sHLA-
G production, has documented a correlation between HLA-G
genetic polymorphisms and sHLA-G concentrations in both CSF
and serum (117). These findings indicate that CSF and serum
sHLA-G levels in MS could be affected by two main HLA-G poly-
morphisms. Moreover, preliminary results from our laboratory
have demonstrated that, MS patients present dimeric sHLA-G
form more frequently than control, in particular in MRI inactive
MS patients (unpublished data), suggesting that large amounts
of biologically active dimeric sHLA-G form could be released
in CSF of MS patients, possibly induced by pharmacological
treatment (118). Nevertheless, in a recent study no association
was found between serum sHLA-G levels, disability progres-
sion, disease MRI activity, and time to conversion from clinically
isolated syndrome (CIS) to clinically definite MS (119). These
findings suggest that the use of sHLA-G levels in CSF should
be taken into consideration as a prognostic marker for moni-
toring disease conversion, activity, progression, and response to
therapy.
HLA-G IMPACT IN VIRAL INFECTIONS
Even if host immune system present several mechanisms to con-
trol viral infections, the viruses have developed several strategies
to counteract host immune defenses (120). HLA-G seems to be
implicated in viral immune-escape from Natural Killer cells (121).
Human immunodeficiency virus type 1 (HIV-1) up-regulates
HLA-G molecules and down-regulates classical HLA-A and -B.
Studies have focused on the expression of HLA-G in monocytes,
which are relevant as reservoirs of HIV-1, and in lymphocytes,
which are more susceptible to infection by HIV-1. Monocytes from
HIV-1 seropositive patients express HLA-G (122) with a possible
association with antiretroviral therapy (HAART), since patients
undergoing HAART present higher levels of HLA-G expression
on monocytes in comparison with untreated and healthy subjects
(122, 123). T cells obtained from HIV-1 seropositive individu-
als have been found to express HLA-G at a higher proportion
(124) and behave like HLA-G+ Treg. Furthermore, on the basis
of HLA-G genetics, it would seem that the HLA-G 14bpINS and
+3142G polymorphisms affect the susceptibility to HIV (125) but
not mother–child transmission (126) in African population.
Human cytomegalovirus is a herpes virus that persists in the
host (127) by means of several strategies to evade the immune
system. HLA-G expression is evidenced during viral reactiva-
tion in macrophages and astrocytoma cells (35) and the lev-
els of expression on monocytes an in serum is higher during
active human cytomegalovirus (HCMV) infection (128). This
up-regulation is proposed to be associated with virus-encoded
homologs of humanIL-10 (cmvIL-10) (129), which prevents NK
cell recognition of infected cells.
There is also evidence to support also a role of HLA-G
molecules in susceptibility and outcome of human papilloma
virus (HPV) infections. The alleles HLA-G 14bp INS, +1537C
(rs12722477), G*01:01, G*01:04, and G*01:06 have been associ-
ated with both high-grade squamous intraepithelial lesions and
cervical cancer, while HLA-G 14bp DEL and +3142C alleles have
been identified as protective (130–135). These results are in agree-
ment with the low levels of HLA-G5 expression in cervical cancer
(136). On the other hand, two researches recognized HLA-G 14bp
DEL allele and +3142C as associated with increased risk of cer-
vical cancer (137, 138), in agreement with increased expression
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of HLA-G in cervical cancer tissues (139) and with the sponta-
neous de-methylation of HLA-G promoter that allows immune-
evasion and the development of precancerous cervical lesions
(140). HLA-G has been also implicated in nasal polyposis devel-
opment in the presence of HPV infection (141). Nasal polyps with
HPV11 infection have shown HLA-G expression on epithelial cells,
while no HLA-G expression has been observed in HPV negative
polyps.
Neurotropic viruses such as herpes simplex virus-1 (HSV-1)
and Rabdovirus (RABV) (142) induce the expression and up-
regulation of membrane and soluble HLA-G molecules in actively
infected neurons with a consequent protection toward host NK
cells.
Hepatitis C virus (HCV) and Hepatitis B virus (HBV) seems to
induce HLA-G expression to control host immune response (125,
143–148).
On the basis of these results, HLA-G proteins are expressed by
virally infected cells as a mechanism to evade host immune con-
trol, preventing T cell and NK cell activation. The main challenge
would be to block HLA-G up-regulation by viral infection, in order
to allow the recognition by immune cells.
INTERACTION OF HLA-G MOLECULES WITH OTHER HLA-Ib
MOLECULES
Other HLA-Ib molecules have been identified: HLA-E and HLA-
F (149, 150) characterized by a low genetic diversity as well as
by a particular expression pattern, structural organization and
functional profile.
Similar to HLA-G, HLA-E forms a complex with β2-
microglobulin. HLA-E is known to play an important role as
immune-modulator during pregnancy and transplantation (151),
inhibiting immune responses by its interaction with CD8+ T cell
receptors (TCRs) (152) and with the CD94/NKG2A inhibitory
receptors of NK cells (153). Meanwhile, this molecule may present
non-self antigens activating immune response (154).
Similar to other HLA molecules, HLA-F can form a complex
with beta2 microglobuli and three splicing variants have been
described. While the presence of HLA-G and HLA-E has been
recently correlated with physiological and pathological conditions,
the clinic-pathological significance of HLA-F is limited. HLA-F is
expressed by peripheral blood B cells upon activation (155) and
is detected in embryonic tissues, including the extravillous tro-
phoblasts invading maternal deciduas, and in spermatozoids (156,
157) and in the serum of patients affected by tumors (158).
Only few data are available on the interaction of HLA-G mol-
ecules with the other HLA-Ib antigens. In physiological condi-
tions, HLA-G molecules interact with HLA-E and co-operate to
inhibit NK cells, mainly at feto-maternal interface, via interaction
with ILT-2 and CD94/NKG2A, respectively (159). In pathological
condition, the interaction between these two molecules facili-
tates the escape of tumor cells from NK cell recognition (160).
In MS, HLA-G and HLA-E molecules are expressed by resident
CNS cells and interact with NK cell and cytotoxic lymphocytes
(161). HLA-G, -E, and -F expression by trophoblasts correlates
with the protection of the fetus from destruction by the mater-
nal immune system, suggesting a co-operation for fetal tissue
preservation.
CONCLUSION
This review aims to focus on the key role of HLA-G molecules
in autoimmune diseases and viral infections. The data herein
summarized suggest that HLA-G may have a crucial role in the
creation of an impaired immune response that characterizes these
pathological conditions.
In fact, it appears even more evident that HLA-G proteins are
involved in the regulation of the immune system during autoim-
munity, such as gastrointestinal, skin, rheumatic and neurologi-
cal diseases and in the immune-escape mechanisms during viral
infections.
Here, we have reviewed a series of experimental and epidemio-
logical studies that support the direct influence of HLA-G proteins
on the balance of immune settings. On this basis, understand-
ing the function of HLA-G in these disorders could help in the
identification of new approaches to control HLA-G production.
For example, it is interesting to note that inflammatory cuta-
neous diseases present a disproportional expression of HLA-G
molecules with respect to controls and that this could gener-
ate autoimmunity. Thus it appears that down/over-expression of
HLA-G may not only act as an immunosuppressive and beneficial
molecule but may also sustain an unbalanced immune stimulation
and autoimmunity. With reference to bowel diseases especially, it
appears clear that the different HLA-G expression levels could
help in the differential diagnosis and consequently in the choice
of appropriate treatment.
Furthermore, several studies have evidenced the possible role
of sHLA-G antigens as a tolerogenic molecules in MS since their
intrathecal production is associated with disease remission. It is
of extreme importance to evaluate the role of HLA-G antigens
in MS pathogenesis, in particular if they are implicated in dis-
ease progression or if they represent an indirect manifestation of
MS inflammation of CNS. Still to be clarified are the functional
differences between HLA-G5 and sHLA-G1, and whether dimers
and monomers exert a different function in MS inflammatory
disease activity. As far as viral infections are concerned, HLA-G
could be considered a target for anti-viral treatment, so increased
knowledge in this field could contribute to identifying different
therapeutic strategies.
Collectively, the results emerging from the literature confirm
the importance of the HLA-G molecule in the pathogenesis and
progression of immune-based diseases and infections, underlin-
ing the relevance of its investigation with the aim to developing
new therapeutic strategies and clinical markers. Meanwhile, the
analysis of the interactions between HLA-G and other HLA-Ib
molecules may be useful to understand the mechanisms for the
creation of immune-suppressive microenvironments.
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